Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.67 |
| ▸ | FTO | Q9C0B1 | 6/20 | 0.67 |
| ▸ | MAOA | P21397 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 9/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.65 |
| ▸ | XDH | P47989 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.65 |
| ▸ | APP | P05067 | 6/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.65 |
| ▸ | IPMK | Q8NFU5 | 5/20 | 0.65 |
| ▸ | IP6K2 | Q9UHH9 | 5/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119125 | 0.88 | ABCB1 (0.67) | CYP1A2ABCB1CYP1A1CYP1B1FTO | |
| SCHEMBL13056264 | 0.87 | CYP1A2 (0.69) | CYP1A2ABCB1CYP1A1CYP1B1FTO | |
| SCHEMBL3755551 | 0.87 | MEN1 (0.69) | CYP1A2ABCB1CYP1A1CYP1B1FTO | |
| SCHEMBL119434 | 0.86 | MEN1 (0.64) | CYP1A2ABCB1CYP1A1CYP1B1FTO | |
| SCHEMBL13056303 | 0.86 | CYP1A2 (0.64) | CYP1A2ABCB1CYP1A1CYP1B1FTO | |
| SCHEMBL19470004 | 0.85 | CYP1A2 (0.72) | CYP1A2ABCB1CYP1A1CYP1B1FTO | |
| Kaempferol SCHEMBL31277388 | 0.83 | MEN1 (0.89) | CYP1A2ABCB1CYP1A1CYP1B1FTO | |
| Kaempferide SCHEMBL29371282 | 0.81 | CYP1A2 (1.00) | CYP1A2ABCB1CYP1A1CYP1B1FTO | |
| Kaempferide SCHEMBL426774 | 0.81 | CYP1A2 (1.00) | CYP1A2ABCB1CYP1A1CYP1B1FTO | |
| Kaempferol SCHEMBL1259228 | 0.80 | MEN1 (1.00) | CYP1A2ABCB1CYP1A1CYP1B1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424541-A2 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | Limerick BioPharma, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010129138-A2 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | PC, PCK1, PYGL | CYP1A2 2311/4885ABCB1 1417/4885CYP1A1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.